Mineralys Therapeutics (MLYS) Assets (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Assets of $652.9 million for Q1 2026, down 1.35% sequentially from $661.8 million in Q4 2025, and up 83.94% YoY from $354.9 million in Q1 2025.
Mineralys Therapeutics (MLYS) Assets (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Assets for 5 years, with the latest figure at $652.9 million in Q1 2026.
- Quarterly Assets rose 83.94% year-over-year to $652.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $652.9 million (up 83.94% YoY) and the FY2025 annual result came in at $661.8 million, up 221.42% from the prior year.
- Assets fell to $652.9 million in Q1 2026 per MLYS's latest filing, from $661.8 million in the prior quarter.
- Over five years, Assets peaked at $661.8 million in Q4 2025 and troughed at $114.4 million in Q4 2022.
- A 5-year average of $356.2 million and a median of $312.5 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2025: Assets retreated 18.17% in 2024, then jumped 221.42% in 2025.
- Over 5 years, Assets stood at $114.4 million in 2022, then surged by 119.88% to $251.6 million in 2023, then dropped by 18.17% to $205.9 million in 2024, then surged by 221.42% to $661.8 million in 2025, then declined by 1.35% to $652.9 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $652.9 million, $661.8 million, and $599.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 667.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 667.85 Mn |
| Mar 31, 2026 | 652.86 Mn |
| Dec 31, 2025 | 661.81 Mn |
| Sep 30, 2025 | 599.95 Mn |
| Jun 30, 2025 | 335.72 Mn |
| Mar 31, 2025 | 354.94 Mn |
| Dec 31, 2024 | 205.90 Mn |
| Sep 30, 2024 | 268.25 Mn |
| Jun 30, 2024 | 318.49 Mn |
| Mar 31, 2024 | 347.25 Mn |
| Dec 31, 2023 | 251.64 Mn |
| Sep 30, 2023 | 277.56 Mn |
| Jun 30, 2023 | 291.22 Mn |
| Mar 31, 2023 | 306.44 Mn |
| Dec 31, 2022 | 114.44 Mn |